GlobeNewswire·Feb 19, 2026, 2:18 AM ET

Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants

Eupraxia Pharmaceuticals Inc. priced a public offering of 6,428,574 common shares at US$7.00 each & pre-funded warrants for 1,428,571 shares at US$6.99999 each.
The offering is expected to generate gross proceeds of approximately US$55 million before deducting underwriting commissions & estimated expenses.
Each pre-funded warrant allows the holder to acquire one common share at a nominal exercise price of C$0.00001 with no expiration date.
Underwriters were granted a 30-day option to purchase an additional 1,178,571 common shares on the same terms.
Cantor & LifeSci Capital serve as joint book-running managers, while Bloom Burton & Craig-Hallum act as co-managers.
The offering is scheduled to close on February 20, 2026, subject to customary conditions including listings on the TSX & Nasdaq.
Net proceeds will primarily fund the advancement of EP-104GI for Eosinophilic Esophagitis, including preclinical studies, Phase 2 trials, Phase 3 preparations, manufacturing, & market development.
A portion of the proceeds will accelerate clinical studies for EP-104GI in additional gastrointestinal indications such as esophageal strictures & fibrostenotic Crohn's disease.
Remaining funds will support R&D for other pipeline candidates, business development, general corporate purposes, & expansion of the intellectual property portfolio.
The offering was made pursuant to a U.S. Form F-10 registration statement & a Canadian base shelf prospectus filed in early 2024.